UBS Group
APRE icon

UBS Group’s Aprea Therapeutics APRE Stock Holding History

UBS Group’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2 Sell
3
-2,150
-100% -$1.79K ﹤0.01% 10369
2026
Q1 		$1.64K Sell
2,153
-308
-13% -$242 ﹤0.01% 9470
2025
Q4 		$2.1K Buy
2,461
+2,458
+81,933% +$3.02K ﹤0.01% 9379
2025
Q3 		$4 Sell
3
-5
-63% -$8 ﹤0.01% 10237
2025
Q2 		$13 Buy
8
+5
+167% +$9 ﹤0.01% 10138
2025
Q1 		$6 Sell
3
-5,932
-100% -$18.6K ﹤0.01% 10133
2024
Q4 		$19.5K Buy
5,935
+5,932
+197,733% +$19.8K ﹤0.01% 7887
2024
Q3 		$8 Hold
3
– – ﹤0.01% 9368
2024
Q2 		$12 Hold
3
– – ﹤0.01% 9336
2024
Q1 		$20 Hold
3
– – ﹤0.01% 9033
2023
Q4 		$14 Hold
3
– – ﹤0.01% 9098
2023
Q3 		$13 Hold
3
– – ﹤0.01% 9181
2023
Q2 		$9 Sell
3
-671
-100% -$2.5K ﹤0.01% 8740
2023
Q1 		$2.99K Sell
674
-613
-48% -$4.53K ﹤0.01% 8403
2022
Q4 		$8.49K Buy
1,287
+990
+333% +$10.4K ﹤0.01% 8769
2022
Q3 		$4K Sell
297
-220
-43% -$3.9K ﹤0.01% 9325
2022
Q2 		$8K Buy
517
+254
+97% +$5.86K ﹤0.01% 8279
2022
Q1 		$10K Buy
263
+259
+6,475% +$10.6K ﹤0.01% 8392
2021
Q4 		$0 Buy
+4
New +$353 ﹤0.01% 10232
2021
Q3 		– Sell
-66
Closed -$6K – 9496
2021
Q2 		$6K Sell
66
-58
-47% -$5.36K ﹤0.01% 8423
2021
Q1 		$13K Buy
124
+89
+254% +$10.4K ﹤0.01% 7725
2020
Q4 		$3K Buy
35
+33
+1,650% +$15.7K ﹤0.01% 7980
2020
Q3 		$1K Sell
2
-157
-99% -$87.9K ﹤0.01% 7760
2020
Q2 		$123K Sell
159
-60
-27% -$39.4K ﹤0.01% 5138
2020
Q1 		$152K Sell
219
-89
-29% -$65.3K ﹤0.01% 4930
2019
Q4 		$283K Buy
+308
New +$170K ﹤0.01% 5335

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group's APRE Position: Q2 2026 in Review

UBS Group reduced its Aprea Therapeutics (APRE) stake by 100% in Q2 2026, selling an estimated $1.79K and leaving 3 shares worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #10369.

UBS Group first reported a position in APRE in Q4 2019 and has held it in 26 quarters since. The position peaked at $283K in Q4 2019. 27 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

  • UBS Group held 3 shares of Aprea Therapeutics worth $2 as of Q2 2026.
  • UBS Group sold 2,150 Aprea Therapeutics shares in Q2 2026, an estimated $1.79K.
  • Aprea Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10369 holding.
  • UBS Group first reported a position in Aprea Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • UBS Group's Aprea Therapeutics position peaked at $283K in Q4 2019.
  • 27 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.